US › Healthcare

Estrella Immunopharma Inc. (ESLA)

US · Healthcare · Biotechnology

$0.53-17.80%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-2.3M

EPS

$-0.05

EPS estimate

$-0.09

EPS came in at -0.05 against a street estimate of -0.09 — a beat of 44.4%.

Key statistics

Market cap

$28.7M

Forward P/E

0.0

P/B

4.13

Book value

$-0.17

EPS (TTM)

$-0.25

52-week high

$3.15

52-week low

$0.58

50-day MA

$0.76

200-day MA

$1.18

Beta

0.89

Analyst view

Analysts rate Estrella Immunopharma Inc. a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $12.00.

Shareholding

Insiders

60.42%

Institutions

11.14%

Largest institutional holders

Fund	Stake
Armistice Capital, LLC	9.53%
Vanguard Capital Management, LLC	0.89%
Wells Fargo & Co	0.61%
Geode Capital Management, LLC	0.37%
Vanguard Fiduciary Trust Co	0.15%
Renaissance Technologies Corp	0.15%
State Street Corp	0.10%
BlackRock Inc	0.09%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Estrella Immunopharma Inc. — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.